ReviewPediatric nephrology (Berlin, Germany)2012
Autoantibodies in systemic lupus erythematosus.
Review in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.Lupus science & medicine · 2024Trial
- 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.PloS one · 2013Trial
- Dietary and Nutritional Factors in Systemic Lupus Erythematosus Pathophysiology: A Scoping Review of the Evidence from In Vitro, In Vivo, and Human Studies.Advances in nutrition (Bethesda, Md.) · 2026Article
- Neonatal lupus erythematosus: an acquired autoimmune disease to be taken seriously.Annals of medicine · 2025Review
- Neonatal lupus erythematosus as a rare trigger of gastrointestinal involvement in neonates.Scientific reports · 2024Article
- Osteopontin as a Biomarker in Chronic Kidney Disease.Biomedicines · 2023Review
- The preliminary association study of osteopontin 707 C/T polymorphism with systemic lupus erythematosus in a Polish population.Postepy dermatologii i alergologii · 2020Article
- In vitro modulatory effect of dehydroepiandrosterone sulfate on apoptosis and expression of apoptosis-related genes in patients with systemic lupus erythematosus.Journal of cellular physiology · 2019Article
- [Acute unilateral non-traumatic enophthalmus].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Article
- EBNA1 IgM-Based Discrimination Between Rheumatoid Arthritis Patients, Systemic Lupus Erythematosus Patients and Healthy Controls.Antibodies (Basel, Switzerland) · 2019Article
- The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients.Clinical rheumatology · 2019Article
- The role of osteopontin in kidney diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Review
- Neonatal Systemic Lupus Erythematosus Syndrome: a Comprehensive Review.Clinical reviews in allergy & immunology · 2017Review
- Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Trends in molecular medicine · 2017Review
- The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus.BMC genetics · 2015Article
- Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus.Frontiers in immunology · 2015Review
- Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets.Journal of inflammation (London, England) · 2015Article
- Role of osteopontin in systemic lupus erythematosus.Archivum immunologiae et therapiae experimentalis · 2014Review
- The complement cascade and renal disease.Archivum immunologiae et therapiae experimentalis · 2014Review
- Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.Autoimmune diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a multifactorial disorder with multigenic inheritance and various environmental factors implicated in its aetiopathogenesis. Despite the multiple mechanisms involved in the aetiology of SLE being elusive, recent studies have made progress in our understanding of the pathogenic mechanisms via abnormal regulation of cell-mediated and humoral immunity that lead to tissue damage. The heterogeneity of the clinical manifestations probably reflects the complexity of the disease pathogenesis itself. The immune system in SLE is characterised by a complex interplay between overactive B cells, abnormally activated T cells and antigen-presenting cells. This interplay leads to the production of an array of inflammatory cytokines, apoptotic cells, diverse autoantibodies and immune complexes that in turn activate effector cells and the complement system, leading to tissue injury and damage which are the hallmarks of the clinical manifestations. SLE patients have dysregulation of inflammatory cytokines, chemokines and immune response-related genes, as well as of the genes involved in apoptosis, signal transduction and the cell cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.